EMEA-000268-PIP01-08 - paediatric investigation plan

naproxen
esomeprazole magnesium trihydrate
PIPHuman

Key facts

Active Substance
  • naproxen
  • esomeprazole magnesium trihydrate
Therapeutic area
Immunology-Rheumatology-Transplantation
Decision number
P/80/2008
PIP number
EMEA-000268-PIP01-08
Pharmaceutical form(s)
Tablet
Condition(s) / indication(s)
  • Ankylosing spondylitis
  • Primary generalised osteoarthritis
  • Rheumatoid arthritis
Route(s) of administration
Oral use
Contact for public enquiries

AstraZeneca AB (Sweden)

E-mail: paediatrics@astrazeneca.com
Phone: +46 855327591
 

Decision type
W: decision granting a waiver in all age groups for all conditions or indications
Decision date

Decision

Share this page